Lexicon Pharmaceuticals, Inc. (LXRX)
NASDAQ: LXRX · Real-Time Price · USD
0.807
-0.074 (-8.34%)
At close: Nov 20, 2024, 4:00 PM
0.810
+0.003 (0.32%)
Pre-market: Nov 21, 2024, 4:02 AM EST
Lexicon Pharmaceuticals Employees
Lexicon Pharmaceuticals had 285 employees as of December 31, 2023. The number of employees increased by 150 or 111.11% compared to the previous year.
Employees
285
Change (1Y)
150
Growth (1Y)
111.11%
Revenue / Employee
$18,347
Profits / Employee
-$759,274
Market Cap
291.87M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Cerus | 637 |
Spok Holdings | 384 |
CVRx, Inc. | 200 |
COMPASS Pathways | 186 |
AC Immune | 161 |
Absci | 155 |
Sanara MedTech | 108 |
Design Therapeutics | 58 |
LXRX News
- 18 hours ago - Lexicon Appoints Ivan H. Cheung to Board of Directors - GlobeNewsWire
- 8 days ago - Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 8 days ago - Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 15 days ago - Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference - GlobeNewsWire
- 15 days ago - Published Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease - GlobeNewsWire
- 20 days ago - Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease - GlobeNewsWire
- 20 days ago - FDA advisers vote against Lexicon Pharma's add-on drug for type 1 diabetes - Reuters
- 5 weeks ago - Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe - GlobeNewsWire